Hematologic Malignancies
Hematologic malignancies are cancers affecting the blood, bone marrow, and lymphatic system, including leukemia, lymphoma, and multiple myeloma. These disorders arise due to abnormal proliferation of blood cells or plasma cells, often caused by genetic mutations, chromosomal translocations, or dysregulated cellular signaling pathways. Leukemia involves overproduction of immature white blood cells, disrupting normal hematopoiesis and causing anemia, infections, and bleeding complications. Lymphoma originates from malignant lymphocytes, affecting lymph nodes and other organs, while multiple myeloma involves clonal expansion of plasma cells in the bone marrow, leading to bone lesions, immunodeficiency, and kidney dysfunction. Diagnostic approaches include complete blood counts, peripheral blood smears, bone marrow biopsy, immunophenotyping via flow cytometry, cytogenetic analysis, and molecular techniques like PCR and next-generation sequencing. Laboratory instruments such as automated hematology analyzers, flow cytometers, fluorescence microscopes, and sequencing platforms ensure accuracy and reproducibility in testing. Therapeutic strategies include chemotherapy, targeted therapy, immunotherapy, monoclonal antibodies, and hematopoietic stem cell transplantation, with emerging treatments such as CAR-T therapy and gene-editing approaches showing promise. The integration of advanced diagnostics with novel therapies enables early detection, precise disease classification, personalized treatment planning, and monitoring of therapeutic responses. This session provides delegates with comprehensive knowledge of the biological mechanisms, state-of-the-art diagnostic tools, laboratory instruments, and innovative treatment options in hematologic malignancies, fostering improved understanding and application in clinical practice.